Legal & General Group
ATOS icon

Legal & General Group’s Atossa Therapeutics ATOS Stock Holding History

Legal & General Group’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-789
Closed -$7.96K – 3428
2025
Q1 		$7.96K Hold
789
– – ﹤0.01% 3217
2024
Q4 		$11.2K Hold
789
– – ﹤0.01% 3232
2024
Q3 		$18K Hold
789
– – ﹤0.01% 3089
2024
Q2 		$14.1K Buy
+789
New +$17.5K ﹤0.01% 3168
2022
Q2 		– Sell
-782
Closed -$15K – 3530
2022
Q1 		$15K Hold
782
– – ﹤0.01% 3294
2021
Q4 		$18K Hold
782
– – ﹤0.01% 3303
2021
Q3 		$38K Hold
782
– – ﹤0.01% 3052
2021
Q2 		$74K Buy
+782
New +$41.4K ﹤0.01% 2824

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Legal & General Group's ATOS Position: Q2 2025 in Review

Legal & General Group sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 789 shares — an estimated $7.96K sold.

Legal & General Group first reported a position in ATOS in Q2 2021 and held it in 8 quarters. The position peaked at $74K in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • Legal & General Group reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 789 Atossa Therapeutics shares in Q2 2025, an estimated $7.96K.
  • Legal & General Group first reported a position in Atossa Therapeutics in Q2 2021 and held it in 8 quarters.
  • Legal & General Group's Atossa Therapeutics position peaked at $74K in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.